Navigation Links
DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza
Date:6/5/2009

Two timely sessions at the DIA 45th Annual Meeting reflect the state of today's global biopharmaceutical environment.

Horsham, PA, USA (Vocus) June 5, 2009 -- The Drug Information Association (DIA) 45th Annual Meeting is the biopharmaceutical industry's largest and longest running global, multidisciplinary conference featuring sessions and preconference tutorials on issues affecting drug discovery and development, including two timely sessions reflecting the state of today's global biopharmaceutical environment.

The public policy/law track features a special session on Labeling Risk: Practical Approaches after Wyeth v. Levine (June 22; 1:30 - 3:00 pm).

In March 2009, The Wall Street Journal reported that the Supreme Court ruling in Wyeth v. Levine stated that pharmaceutical companies are not necessarily shielded from failure to warn product liability lawsuits in state courts when the US FDA has determined that approved labeling appropriately explains risk information, This session will explore practical approaches pharmaceutical companies should consider when disseminating risk information to minimize failure to warn liability and to maximize the possibility such liability is preempted.

"We will delve deep into the legal benefits of preemptions, describe regulatory and documentation strategies that maximize the availability of preemption in failure-to-warn lawsuits, and identify effective risk communication strategies," says Session Chair Patrick C O'Brien, JD, PharmD, Partner, Burke O'Neil LLC, United States.

Speakers include:

 
  • John B Moriarty, JD, Senior Vice President, Elan Pharmaceuticals, United States
  • Sandra A. Milligan, JD, MD, Executive Director, Amgen Inc., United States
Mary K. Pendergast, JD, LLM, President, Pendergast Consulting, United States
This year's biotechnology track includes a timely session on Regulatory Methods to Facilitate the Approval of Biological Products to Address Pandemic Influenza (June 22, 1:30 - 3:00 pm).

This session incorporates descriptions of novel regulatory mechanisms for vaccine approval with a discussion of successful applications for pandemic influenza.

"This must-attend session will attempt to identify novel regulatory approaches to vaccine approval, industry approaches toward interactions with the FDA, and novel biochemical methods for the development of vaccines," explains Session Chair Richard M Lewis, PhD, CEO, Access BIO, United States.

Speakers include:

 
  • Jean L Hu-Primmer, MS, Program Manager, Pandemic and Emerging Threat Preparedness, OD, CBER, USFDA
  • John Purves, PhD, Head of Sector, Quality of Medicines, European Medicines Agency
  • Ozzie Berger, Senior Director and Head, Influenza Vaccines, US Regulatory Affairs, Biologicals, GlaxoSmithKline

About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team.

Contact:
Joe Krasowski
+1-215-293-5812

Bonnie Shaw
Clearpoint Agency, Inc.
+1-858-724-2500

# # #

Read the full story at http://www.prweb.com/releases/DIA/45th_Annual_Meeting/prweb2502964.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Council of State and Territorial Epidemiologists Annual Conference Begins June 7 in Buffalo, NY
2. NeoGenomics to Present at Noble Financials 5th Annual Equity Conference on Monday, June 8th
3. Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference
4. NuVasive to Present at the 8th Annual Needham Life Sciences Conference
5. Maggianos Little Italy(R) Celebrates Sixth Annual Eat-A-Dish for Make-A-Wish(R) in Chicago
6. Trubion to Present at the 8th Annual Needham Life Sciences Conference
7. Photos: Tommy & Thalia Mottola Honored at 7th Annual FedEx/St. Jude Angels & Stars Gala
8. Accuray Incorporated to Present at Eighth Annual Needham Life Sciences Conference
9. Medivation to Present at 8th Annual Needham Life Sciences Conference
10. Isis Pharmaceuticals to Present at Goldman Sachs 30th Annual Global Healthcare Conference
11. Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza 
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
(Date:12/8/2016)...  A new study by a pair of Geisinger ... therapy to treat chronic pain is not only ineffective, ... consequences, including death. Palliative care physicians ... , M.D., authored the study which provides a review ... study was published in the December 2016 edition of ...
Breaking Medicine Technology: